NasdaqGS:GILDBiotechs
Gilead Sciences (GILD) Margin Surge Tests Cautious Growth Narratives After FY 2025 Results
Gilead Sciences (GILD) just wrapped FY 2025 with fourth quarter revenue of US$7.9b and basic EPS of US$1.76, supported by trailing twelve month revenue of US$29.4b and EPS of US$6.84. Over recent quarters, revenue has moved from US$6.7b in Q1 2025 to US$7.1b in Q2 and US$7.8b in Q3, while quarterly EPS shifted from US$1.06 to US$1.57, US$2.46 and then US$1.76, setting up a year where stronger net profit margins and higher full year earnings put profitability in clear focus for investors.
See...